Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong Zong

Showing results (231-240 of 240) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 240 results.
The Prostate|June 30, 2018
A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancerShanshan Zhao, Amy Leonardson, Milan S Geybels, et al.
JAMA Oncology|July 31, 2025
Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical TrialZhonghua Tao, Jian Zhang, Qiufan Zheng, et al.
International Journal of Cancer|November 29, 2022
Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trialShuiling Jin, Ruihua Zhao, Chuang Zhou, et al.
Ebiomedicine|January 13, 2024
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ studyLin Yang, Wen Zhang, Nanfeng Fan, et al.
JAMA Oncology|June 1, 2026
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical TrialPeng Yuan, Yunjiang Liu, Wei Li, et al.
Molecular Cancer|March 13, 2022
Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m<sup>6</sup>A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progressionHao Liu, Danxiu Li, Lina Sun, et al.
Annals of Translational Medicine|January 20, 2023
Apatinib in the treatment of gastric cancer in Henan Province: a multicenter prospective real-world observational study (Ahead-HAP01)Yijie Ma, Weijie Zhao, Peichun Sun, et al.
Annals of Internal Medicine|October 16, 2013
Prevalence of unruptured cerebral aneurysms in Chinese adults aged 35 to 75 years: a cross-sectional studyMing-Hua Li, Shi-Wen Chen, Yong-Dong Li, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2024
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II studyXiangrui Meng, Junsheng Wang, Jin Xia, et al.
Signal Transduction and Targeted Therapy|December 18, 2025
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trialYongmei Yin, Qingyuan Zhang, Tao Sun, et al.
Pageof 24

Showing results (231-240 of 240) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 240 results.
The Prostate|June 30, 2018
A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancerShanshan Zhao, Amy Leonardson, Milan S Geybels, et al.
JAMA Oncology|July 31, 2025
Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical TrialZhonghua Tao, Jian Zhang, Qiufan Zheng, et al.
International Journal of Cancer|November 29, 2022
Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trialShuiling Jin, Ruihua Zhao, Chuang Zhou, et al.
Ebiomedicine|January 13, 2024
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ studyLin Yang, Wen Zhang, Nanfeng Fan, et al.
JAMA Oncology|June 1, 2026
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical TrialPeng Yuan, Yunjiang Liu, Wei Li, et al.
Molecular Cancer|March 13, 2022
Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m<sup>6</sup>A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progressionHao Liu, Danxiu Li, Lina Sun, et al.
Annals of Translational Medicine|January 20, 2023
Apatinib in the treatment of gastric cancer in Henan Province: a multicenter prospective real-world observational study (Ahead-HAP01)Yijie Ma, Weijie Zhao, Peichun Sun, et al.
Annals of Internal Medicine|October 16, 2013
Prevalence of unruptured cerebral aneurysms in Chinese adults aged 35 to 75 years: a cross-sectional studyMing-Hua Li, Shi-Wen Chen, Yong-Dong Li, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2024
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II studyXiangrui Meng, Junsheng Wang, Jin Xia, et al.
Signal Transduction and Targeted Therapy|December 18, 2025
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trialYongmei Yin, Qingyuan Zhang, Tao Sun, et al.
Pageof 24